Mutant calreticulin in myeloproliferative neoplasms.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
19 12 2019
Historique:
received: 12 08 2019
accepted: 19 09 2019
pubmed: 29 9 2019
medline: 25 3 2020
entrez: 29 9 2019
Statut: ppublish

Résumé

Recurrent mutations in calreticulin are present in ∼20% of patients with myeloproliferative neoplasms (MPNs). Since its discovery in 2013, we now have a more precise understanding of how mutant CALR, an endoplasmic reticulum chaperone protein, activates the JAK/STAT signaling pathway via a pathogenic binding interaction with the thrombopoietin receptor MPL to induce MPNs. In this Spotlight article, we review the current understanding of the biology underpinning mutant CALR-driven MPNs, discuss clinical implications, and highlight future therapeutic approaches.

Identifiants

pubmed: 31562135
pii: S0006-4971(20)73128-9
doi: 10.1182/blood.2019000622
pmc: PMC6923668
doi:

Substances chimiques

CALR protein, human 0
Calreticulin 0
Neoplasm Proteins 0
Receptors, Thrombopoietin 0
STAT Transcription Factors 0
MPL protein, human 143641-95-6
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2242-2248

Subventions

Organisme : NCI NIH HHS
ID : K12 CA087723
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA206963
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131835
Pays : United States

Informations de copyright

© 2019 by The American Society of Hematology.

Références

PLoS Med. 2006 Jul;3(7):e270
pubmed: 16834459
Blood. 2018 Feb 8;131(6):649-661
pubmed: 29282219
Am J Hematol. 2016 Feb;91(2):211-9
pubmed: 26573090
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Blood Cancer J. 2018 Jan 10;8(1):2
pubmed: 29321520
J Immunother Cancer. 2018 Jul 13;6(1):70
pubmed: 30001747
Leukemia. 2014 Jul;28(7):1552-5
pubmed: 24504025
Blood. 2016 Mar 10;127(10):1325-35
pubmed: 26668133
Leukemia. 2015 Jan;29(1):249-52
pubmed: 25212275
Nature. 2019 Jul;571(7765):355-360
pubmed: 31270458
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Blood. 2014 Mar 6;123(10):1544-51
pubmed: 24366362
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615
pubmed: 25037629
Haematologica. 2014 Jul;99(7):1184-90
pubmed: 24895336
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
Blood. 2015 Mar 5;125(10):1679-81
pubmed: 25745188
Blood Cancer J. 2019 Jan 17;9(2):8
pubmed: 30655510
Leukemia. 2019 Jan;33(1):122-131
pubmed: 29946189
Am J Clin Pathol. 2015 May;143(5):635-44
pubmed: 25873496
Ann Hematol. 2017 May;96(5):725-732
pubmed: 28161773
Am J Hematol. 2014 Aug;89(8):E121-4
pubmed: 24753125
Am J Hematol. 2018 Mar;93(3):348-355
pubmed: 29164670
J Hematol Oncol. 2016 May 13;9(1):45
pubmed: 27177927
Blood Cancer J. 2018 Jul 31;8(8):72
pubmed: 30065290
Blood. 2016 Mar 10;127(10):1307-16
pubmed: 26817954
Blood. 2016 Mar 10;127(10):1317-24
pubmed: 26608331
Blood. 2016 Jun 23;127(25):3253-9
pubmed: 27013444
Leukemia. 2014 Jul;28(7):1568-70
pubmed: 24569778
Blood. 2019 Jun 20;133(25):2669-2681
pubmed: 30902807
Haematologica. 2015 Jul;100(7):893-7
pubmed: 25934766
Exp Hematol. 2016 Sep;44(9):817-825.e3
pubmed: 27185380
Blood. 2017 Jun 15;129(24):3227-3236
pubmed: 28351937
Haematologica. 2016 Aug;101(8):926-31
pubmed: 27175028
Blood. 2014 Mar 6;123(10):1552-5
pubmed: 24371211
Am J Hematol. 2016 May;91(5):503-6
pubmed: 26890983
Blood. 2014 Aug 14;124(7):1062-9
pubmed: 24986690
J Clin Oncol. 2018 Jun 10;36(17):1769-1770
pubmed: 29708808
Blood. 2006 Nov 15;108(10):3472-6
pubmed: 16868251
Leukemia. 2018 Jul;32(7):1631-1642
pubmed: 29654267
Leukemia. 2019 Aug 30;:null
pubmed: 31471561
Clin Transl Oncol. 2017 Jul;19(7):874-883
pubmed: 28205126
Blood Cancer J. 2015 Nov 27;5:e369
pubmed: 26617062
JCI Insight. 2018 Nov 15;3(22):
pubmed: 30429377
BioDrugs. 2016 Jun;30(3):219-23
pubmed: 27041108
Biochem J. 2009 Feb 1;417(3):651-66
pubmed: 19133842
Leukemia. 2016 Feb;30(2):431-8
pubmed: 26449662
Leukemia. 2017 May;31(5):1136-1144
pubmed: 27807369
Cancer Discov. 2016 Apr;6(4):368-81
pubmed: 26951227
Leukemia. 2017 Dec;31(12):2726-2731
pubmed: 28561069
Leukemia. 2018 Feb;32(2):429-437
pubmed: 28676668
Blood. 2015 Dec 10;126(24):2585-91
pubmed: 26486786
Leukemia. 2016 Aug;30(8):1759-63
pubmed: 26883579
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Blood. 2014 Oct 9;124(15):2465-6
pubmed: 25301336
J Biol Chem. 2018 Jun 22;293(25):9555-9569
pubmed: 29769311
Oncogene. 2019 Mar;38(10):1651-1660
pubmed: 30846848
J Clin Oncol. 2018 Feb 1;36(4):310-318
pubmed: 29226763
Blood. 2018 Feb 15;131(7):782-786
pubmed: 29288169
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Br J Haematol. 2016 Jun;173(6):938-40
pubmed: 26303809
Cancer Discov. 2019 Sep;9(9):1192-1207
pubmed: 31266769
Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101
pubmed: 28389256
Leukemia. 2014 Jul;28(7):1472-7
pubmed: 24402162
Ann Hematol. 2016 Sep;95(9):1391-8
pubmed: 27376361
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187

Auteurs

Joan How (J)

Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and.

Gabriela S Hobbs (GS)

Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and.

Ann Mullally (A)

Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Broad Institute, Cambridge, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH